Protara CMO Jathin Bandari resigns effective April 11; interim oversight assigned

Protara Therapeutics, Inc.

CMO Jathin Bandari resigns effective April 11, 2024 to explore academic opportunities; consulting through July 11.
Severance includes $365,386 lump sum (9 months salary), $164,424 bonus, COBRA for 9 months, and pro-rata vesting of 11,993 options + 5,886 RSUs.
Interim oversight: Jacqueline Zummo (SVP & Chief Scientific Ops Officer) leads medical staff, advised by board member Richard Levy, M.D.
Company plans to search for a new Chief Medical Officer.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jathin Bandari

Chief Medical Officer

TARA · Protara Therapeutics, Inc.

Effective: 2024-04-11
Filed: March 18, 2024, 7:59 PM ET

On March 18, 2024, Protara Therapeutics, Inc. (the “Company”) announced that Jathin Bandari, M.D., Chief Medical Officer of the Company, will be resigning from the Company to explore other opportunities, including devoting more time to academic work, effective as of April 11, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jathin Bandari resigned as Chief Medical Officer at Protara Therapeutics, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On March 18, 2024, Protara Therapeutics, Inc. (the “Company”) announced that Jathin Bandari, M.D., Chief Medical Officer of the Company, will be resigning from the Company to explore other opportunities, including devoting more time to academic work, effective as of April 11, 2024.

View on SEC.gov

Protara Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-023589

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.